

ST5 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6249a

Specification

ST5 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P78524
Other Accession NP_005409

ST5 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 6764

Other Names

Suppression of tumorigenicity 5 protein, DENN domain-containing protein 2B, HeLa tumor suppression 1, ST5, DENND2B, HTS1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6249a was selected from the C-term region of human ST5 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ST5 Antibody (C-term) Blocking Peptide - Protein Information

Name DENND2B (HGNC:11350)

Function

[Isoform 1]: May be involved in cytoskeletal organization and tumorogenicity. Seems to be involved in a signaling transduction pathway leading to activation of MAPK1/ERK2. Plays a role in EGFR trafficking from recycling endosomes back to the cell membrane (PubMed:29030480).

Cellular Location

[Isoform 1]: Cytoplasm, cell cortex. Cell membrane. Recycling endosome. Note=Colocalizes with RAB13 and ITSN1 at cytoplasmic vesicles that are most likely recycling endosomes Colocalizes with the cortical actin cytoskeleton



Tissue Location

Widely expressed with the exception of peripheral blood lymphocytes. Isoform 1 is expressed in several epithelial and fibroblast (including tumorigenic) but absent in lymphoid cell lines (at protein level). Isoform 3 is expressed in primary cell or weakly tumorigenic but not in tumorigenic cell lines (at protein level)

ST5 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

ST5 Antibody (C-term) Blocking Peptide - Images

ST5 Antibody (C-term) Blocking Peptide - Background

ST5 was identified by its ability to suppress the tumorigenicity of Hela cells in nude mice. The protein contains a C-terminal region that shares similarity with the Rab 3 family of small GTP binding proteins. This protein preferentially binds to the SH3 domain of c-Abl kinase, and acts as a regulator of MAPK1/ERK2 kinase, which may contribute to its ability to reduce the tumorigenic phenotype in cells.

ST5 Antibody (C-term) Blocking Peptide - References

Majidi, M., et al., J. Biol. Chem. 275(9):6560-6565 (2000). Hubbs, A.E., et al., Oncogene 18(15):2519-2525 (1999). Majidi, M., et al., J. Biol. Chem. 273(26):16608-16614 (1998). Lichy, J.H., et al., Nucleic Acids Res. 24(23):4700-4708 (1996). Lichy, J.H., et al., Cell Growth Differ. 3(8):541-548 (1992).